Özet:

Objective Metastasis and pathological staging are considered the primary prognostic indicators for invasive melanoma (IM). Pathological staging is determined by evaluating tumor size, depth of invasion, ulceration, and mitotic index. Our study aims to explore the relationship between the prognosis of BRAF V600E and CD271 and their immunohistochemical expressions, as well as clinicopathological parameters. Materials and Methods Our study analyzed 47 cases of IM that were observed between December 2010 and May 2017 at Süleyman Demirel University's Department of Pathology. These cases were assessed using BRAF V600E and CD271 markers, and their correlation with primary and metastatic IM, as well as survival rates, were examined using immunohistochemical analysis. We also investigated the relationship between referral, lymphocytic infiltration, pigmentation, mitosis, Breslow depth, lack of metastasis screening, age, gender, and survival to provide a comprehensive understanding of the factors that may influence the disease progression and patient outcomes. Results The age of the primary IM patients ranged from 35 to 93 years old, with an average of 64.12 ± 20.35 years. The age of the metastatic IM patients ranged from 35 to 89 years old, with an average of 69 ± 13.42 years. Our analysis did not reveal any statistically significant differences in age between these two groups. Significant statistical differences were observed between primary IM and metastatic IM in terms of ulceration and mitotic index. However, there were no significant differences between these two groups in Breslow tumor thickness, lymphocytic infiltration, pigmentation, or the expression of CD271 and V600E. In terms of survival, statistically significant differences were observed in relation to Breslow tumor thickness, ulceration, and the intensity of BRAF V600E expression, as well as between individuals with and without expression of BRAF V600E, specifically in cases with a 3+ expression intensity. No significant differences were observed in relation to gender, pigmentation, BRAF V600E percentage of expression, CD271 expression intensity, or survival. We did not determine a statistically significant difference between primary and metastatic IM groups and survival in terms of CD271 expression severity and percentage in our study. Conclusion In summary, our findings suggest that the expression of BRAF V600E is associated with prognosis, with patients without this expression exhibiting a higher survival rate. However, our results indicate that the survival rate decreases as the intensity of expression increases.